Literature DB >> 10789875

Predicting haloperidol occupancy of central dopamine D2 receptors from plasma levels.

P B Fitzgerald1, S Kapur, G Remington, P Roy, R B Zipursky.   

Abstract

Positron emission tomography (PET) is increasingly being used to study dopamine receptor occupancy and the clinical effects of antipsychotic medication. Dopamine D2 receptor occupancy has been shown to predict several clinical effects of antipsychotic medication including therapeutic response, motor and endocrine side-effects. Plasma levels may be used as a surrogate marker for central occupancy if the relationship between these two measures may be accurately described. This study was designed to test the capacity of a previously derived relationship equation (%D2 occupancy=plasma level/ED50+plasma level, where ED50= 0.40 ng/ml) to predict striatal D2 occupancy from plasma level. Twenty-one patients receiving treatment with low dose haloperidol underwent a 11C-raclopride PET scan to measure D2 occupancy. The D2 occupancy levels were accurately predicted by use of the previously generated equation with only a small degree of error (3.89% CI 0.45-7.33). Predicted and measured D2 occupancy values correlated closely (Pearson's r=0.864, P=0.003). The study indicates that reliable prediction of D2 occupancy from plasma levels is possible. This provides a potentially useful surrogate measure of D2 occupancy for research and possibly clinical practice, as the routine use of PET to measure occupancy levels is not feasible.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10789875     DOI: 10.1007/s002139900333

Source DB:  PubMed          Journal:  Psychopharmacology (Berl)        ISSN: 0033-3158            Impact factor:   4.530


  8 in total

1.  In silico prediction of optimal in vivo delivery properties using convolution-based model and clinical trial simulation.

Authors:  Roberto Gomeni; Carla Dangeli; Alan Bye
Journal:  Pharm Res       Date:  2002-01       Impact factor: 4.200

2.  Elevated DISC1 transcript levels in PBMCs during acute psychosis in patients with schizophrenia.

Authors:  Ann Olincy; Robert House; Bifeng Gao; Peter Recksiek; Tzu Lip Phang; Bernadette Sullivan; Jeff P Hollis; Janet Hopkins; Ted Shade; Michael G Edwards; Ruby Vianzon; Cory Griffiths; John Ceilley; Roger W Helfrich; Jonathan Ritvo; Erica Weis; David Weiss; Judith Gault
Journal:  Transl Biomed       Date:  2011

3.  Effects of antipsychotic treatment on psychopathology and motor symptoms. A placebo-controlled study in healthy volunteers.

Authors:  Tanja Veselinović; Holger Schorn; Ingo Vernaleken; Katharina Schiffl; Christoph Hiemke; Gerald Zernig; Ruben Gur; Gerhard Gründer
Journal:  Psychopharmacology (Berl)       Date:  2011-06-04       Impact factor: 4.530

4.  Mechanisms of action of antipsychotic drugs of different classes, refractoriness to therapeutic effects of classical neuroleptics, and individual variation in sensitivity to their actions: Part I.

Authors:  R Miller
Journal:  Curr Neuropharmacol       Date:  2009-12       Impact factor: 7.363

5.  Mechanisms of action of antipsychotic drugs of different classes, refractoriness to therapeutic effects of classical neuroleptics, and individual variation in sensitivity to their actions: Part II.

Authors:  R Miller
Journal:  Curr Neuropharmacol       Date:  2009-12       Impact factor: 7.363

6.  Tardive dyskinesia in relation to estimated dopamine D2 receptor occupancy in patients with schizophrenia: analysis of the CATIE data.

Authors:  Kazunari Yoshida; Robert R Bies; Takefumi Suzuki; Gary Remington; Bruce G Pollock; Yuya Mizuno; Masaru Mimura; Hiroyuki Uchida
Journal:  Schizophr Res       Date:  2014-02-01       Impact factor: 4.939

7.  Acute effects of single-dose aripiprazole and haloperidol on resting cerebral blood flow (rCBF) in the human brain.

Authors:  Rowena Handley; Fernando O Zelaya; A A T Simone Reinders; Tiago Reis Marques; Mitul A Mehta; Ruth O'Gorman; David C Alsop; Heather Taylor; Atholl Johnston; Steve Williams; Philip McGuire; Carmine M Pariante; Shitij Kapur; Paola Dazzan
Journal:  Hum Brain Mapp       Date:  2012-03-25       Impact factor: 5.038

8.  A review of a recently published guidelines' "strong recommendation" for therapeutic drug monitoring of olanzapine, haloperidol, perphenazine, and fluphenazine.

Authors:  Christopher Noel
Journal:  Ment Health Clin       Date:  2019-07-01
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.